• Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 6,900.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.10
+0 (0.00%)

This chart shows the closing price for VAXX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaxxinity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VAXX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VAXX

Analyst Price Target is $7.00
▲ +6,900.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Vaxxinity in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 6,900.00% upside from the last price of $0.10.

This chart shows the closing price for VAXX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Vaxxinity. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/7/2023Robert W. BairdInitiated CoverageOutperform$7.00Low
4/27/2022Evercore ISIInitiated CoverageIn-LineLow
12/7/2021Jefferies Financial GroupInitiated CoverageBuy$18.00High
12/6/2021Bank of AmericaInitiated CoverageBuy$21.00High
(Data available from 7/23/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/26/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/25/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/25/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/24/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Vaxxinity logo
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Read More

Today's Range

Now: $0.10
Low: $0.01
High: $0.37

50 Day Range

MA: $0.17
Low: $0.05
High: $0.40

52 Week Range

Now: $0.10
Low: $0.01
High: $2.82

Volume

38,979 shs

Average Volume

1,211,167 shs

Market Capitalization

$12.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaxxinity?

The following sell-side analysts have issued stock ratings on Vaxxinity in the last year: Robert W. Baird.
View the latest analyst ratings for VAXX.

What is the current price target for Vaxxinity?

1 Wall Street analysts have set twelve-month price targets for Vaxxinity in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 6,900.0%. Robert W. Baird has the highest price target set, predicting VAXX will reach $7.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $7.00 for Vaxxinity in the next year.
View the latest price targets for VAXX.

What is the current consensus analyst rating for Vaxxinity?

Vaxxinity currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VAXX will outperform the market and that investors should add to their positions of Vaxxinity.
View the latest ratings for VAXX.

What other companies compete with Vaxxinity?

How do I contact Vaxxinity's investor relations team?

The company's listed phone number is 254-244-5739 and its investor relations email address is [email protected]. The official website for Vaxxinity is www.vaxxinity.com. Learn More about contacing Vaxxinity investor relations.